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Increased Central Adiposity may not Underlie the Marked Elevation of IL-6 in
Diabetes Mellitus Patients in South-West, Nigeria
Adiposité  Centrale  Accrue  ne  Pourrait  pas  Expliquer  L’élévation Marquée  D’il-6  Chez  Les
Patients  de  Diabète  Sucré  Dans  le Sud-Ouest Du Nigéria
E. K. Oghagbon*, K. A. Jimoh†, O. Olaosebikan‡, L. Harbige§
ABSTRACT
BACKGROUND: Chronic inflammation is linked to disorders
of obesity, insulin resistance and DM2. This reflects as
increase in proinflammatory cytokines including IL-6. In
Nigeria, there is no study that has measured IL-6 in diabetics,
in spite of having the highest number of diabetics in Africa.
METHODS: The twenty-eight DM2 patients and 13 controls
recruited for this study had their BP, BMI, waist
circumference (WC) and waist-hip-ratio (WHR) measured.
They also had fasting plasma IL-6, fasting plasma glucose,
total cholesterol (TC), Triglyceride (Tg), high density
lipoprotein cholesterol (HDL-C), urea, creatinine, aspartate
transaminases (AST), alanine transferases (ALT), total protein
(TP) and albumin determined.
RESULTS:  Mean age was 51.83 years ± 13.28, with diabetics
significantly older than controls (56.61yrs. ±9.62 vs. 41.54
years ± 14.53) P < 0.05. The mean IL-6 in diabetics (194.77pg/
ml ± 166.16) was significantly higher than controls’ (26.29pg/
ml ± 6.65) at p < 0.01.  No significant difference in mean BMI
in diabetics and controls. But WC and WHR of diabetics
(100.75cm ± 18.47; 1.01 ± 0.14) were significant higher than
in controls (88.77cm ± 13.36; 0.88 ± 0.07) at p < 0.05 (WC; p
value 0.043) and p < 0.01(WHR; p value 0.002).  Among
diabetics, there were significant correlations between IL-6
and Tg (p<0.01, r = 0.007**), IL-6 and LDL-C (p<0.05, r =
0.028*), IL-6 and AST (p<0.05, r = 0.041*) and IL-6 and ALT
(p<0.01, r = 0.004**)
CONCLUSION: Elevated IL-6 in DM2 patients in South West
Nigeria correlates with liver transaminases and not increased
markers of central adiposity.  WAJM 2014; 33(2): 130–135.
Keywords: IL-6, inflammation, diabetes mellitus type 2,
abdominal adiposity.
RÉSUMÉ
CONTEXTE: L’inflammation chronique est associée à des troubles
de l’obésité,  à l’insulino-résistance et au diabète  de Type 2 (DM2).
Cela se reflète comme une augmentation des cytokines pro-
inflammatoires dont  l’IL-6. Au Nigeria, il n’y a  aucune étude qui a
mesurée l’IL-6  chez  les diabétiques, en dépit d’avoir le plus grand
nombre de diabétiques en Afrique.
METHODES:  Les vingt-huit patients DM2 et 13 contrôles recrutés
pour cette étude ont eu leur BP,  l’IMC,  le tour de taille (TT) et taille-
hanche-ratio  (THR) mesurées. Ils avaient également eu un taux  sanguin
d’  IL-6  à jeun ,  une glycémie à jeun, le  cholestérol total (CT), les
triglycérides (TG), la lipoprotéines de haute densité (LDH -C),  l’urée,
la créatinine,   l’aspartate  transaminase  (ASAT), transférases alanine
transférase  (ALAT), protéine totale (PT) et de l’albumine sont
déterminés.
RÉSULTATS:  L’âge  moyen  était 51,83 années ± 13,28, avec des
diabétiques significativement plus âgés que les témoins (56.61yrs. ±
9,62 vs 41,54 années ± 14,53) P < 0,05. La moyenne de l’IL-6 chez
les diabétiques (194.77pg/ml ± 166,16) était significativement plus
élevée que chez les témoins (26.29pg/ml ± 6,65) à p < 0,01.  Il n’y a
aucune différence significative dans l’IMC moyen chez les diabétiques
et les contrôles. Mais  le TT  et  le THR  des diabétiques (100.75cm
± 18,47; 1,01 ± 0,14) étaient significativement plus élevés  que chez
les témoins (88.77cm ± 13,36; 0,88 ± 0,07) à p < 0,05 (TT,  valeur p
de 0,043) et p < 0,01 (THR  valeur p de 0,002). Parmi les diabétiques,
il y avait des corrélations significatives entre l’IL-6 et TG (p < 0,01,
r = 0,007 **), IL-6 et C-LDL (p < 0.05, r = 0,028 *), IL-6 et ASAT (p
< 0,05, r = 0,041 *) et de l’IL-6 et ALAT (p < 0,01, r = 0,004 **).
CONCLUSION:  L’élévation de l’IL-6  chez les patients de DM2
dans sud ouest Nigeria corrèle avec les  transaminases hépatiques et
non  pas  avec une augmentation des marqueurs de l’adiposité centrale.
WAJM 2014; 33 (2): 130–135.
Mots clés:  IL-6, l’inflammation, le diabète sucré de type 2, l’adiposité
abdominale
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INTRODUCTION
In 1993, it was reported that
inflammation is associated with metabolic
disorders such as obesity, insulin
resistance and diabetes mellitus type 2
(DM2),1 and this was later observed to
involve the body’s innate immune
system2 consisting of sentinel trouble-
shooting cells such as macrophages,
endothelial and dendritic cells. The
functions of these cells include
recognising and neutralising environ-
mental threats through the action of
pattern-recognition receptors (PRRs)
and release of proinflammatory
cytokines.3
Proinflammatory cytokines such as
IL6 among others has been associated
with obesity, insulin resistance and
diabetes mellitus.4–9 Commonly measured
cytokine markers in DM2 patients are
CRP, IL-6 and TNF-alpha/TNF-a-receptor
2.8–11 It is known that these three cytokine
markers tend to relate together in that
CRP which is primarily synthesised in the
liver is regulated mainly by TNF-alpha
and IL-6.12
Various studies have consistently
shown elevated CRP and TNF-alpha  in
diabetes mellitus patients8–11,13–15 with a
tendency for these cytokines to express
some ethnic variations.10,14,15
In this present study, we chose to
investigate the levels of IL-6 in Nigerian
type 2 diabetics, especially as it appears
to be consistently elevated and
independently associated with diabetes
mellitus.10–15
This study became necessary given
the increasing prevalence of DM2 in
developing countries including sub-
Saharan Africa.16,17 Nigeria in particular
has the highest number of diabetes
mellitus patients in Africa18 and the
disease prevalence has been on the rise,
yet there is no study that has measured
such an important inflammatory marker;
IL6,  in  Nigerian  diabetics.  Since  the
1960s, the prevalence of diabetes mellitus
in different populations in Nigeria rose
from less than 1%19 to about 6.8%.20 It is
hoped that this study could reveal some
peculiar associated risk factors in Nigeria
diabetics that could be exploited in
reducing the rising prevalence of the
disease and therefore help in addressing
the high mortality/morbidity from the
disease among Nigerians.21
MATERIALS AND METHOD
Forty one subjects were recruited
for this study out of which 23 were type
II diabetics attending the Diabetic Clinic
of Federal Medical Centre, Ekiti State,
Nigeria. The eighteen control subjects
were  non-diabetic  patients  who  were
seen at the General Out-patient Clinics
of the same hospital. The inclusion
criteria for the diabetic subjects were
attendance at the diabetic clinic and
fasting plasma glucose of more than
7mmol/L on more than two occasions
after two weeks of initial testing.
After inclusion in the study, all the
subjects had their blood pressure
(systolic blood pressure; SBP, diastolic
blood pressure; DBP) measured, body
mass index (BMI; kg/m2) was determined
from weight (kilogram) and height
(metres), waist circumference (WC) and
waist-hip-ratio (WHR) were also
recorded.
Venous blood samples were taken
on the morning after an overnight fast of
10–16 hours. Blood sample was taken for
measurement of plasma levels of fasting
plasma glucose, total cholesterol (TC),
Triglyceride (Tg), high density
lipoprotein cholesterol (HDL-C), urea,
creatinine, aspartate transaminases
(AST), alanine transferases (ALT), total
protein (TP), albumin and IL-6. Low
density lipoprotein cholesterol (LDL-C)
was determined from Freldwald fomula as
long as the level of plasma Tg was not
more than 400mg/dl.
To measure IL-6 in plasma of the
subjects, we made use of R&D IL-6
DuoSet ELISA Development kit and the
manufacturer ’s instructions were
followed in assaying for IL-6 in our
subjects’ samples.
The absorption of the final solutions
in each of the ELISA well was determined
by a microplate reader (Mikroscan) set
to 450 nm and the mean value was
determined for each study subject and
standard sample. A standard curve was
determined by plotting the mean
absorbance for each standard on the
y-axis against the concentration on the
x-axis and then drawing a best fit curve
through the points on the graph.
Calculation of the actual concentration
of IL-6 in pg/ml was deduced from formula
obtained from a regression analysis of
the curve.
RESULTS
The study comprised of 41 subjects
out of whom 28 were diabetics and 13
non-diabetic controls. Among the
diabetics, 10 (35.7%) were males and 18
(64.3%) males. The mean age of the whole
population was 51.83 years ± 13.28, but
the mean age for diabetics was 56.61
years ± 9.62. The diabetics were
significantly older than controls (41.54
years ± 14.53) P < 0.05
In the diabetics, twenty (20) of them
were put on oral hypoglycaemic agents
(OHA), three (3) on insulin and three (3)
on both agents (OHA and Insulin). Two
of these patients were recently diagnosed
and yet to be commenced on drugs at the
time of the study. Among the diabetics
and controls, there was no significant
difference in the means of the variables
when they grouped according to their
gender. This supposes that the gender
of the subjects did not affect mean values
of the variables.
In the diabetic population, twenty
(71.4%) were on oral hypoglycaemic
agents, three on insulin (10.7%) and three
were on a combination of insulin and oral
hypoglycaemic agents (10.7%). The other
two (7.1%) were on dietary mani-
pulations.
There was a significant difference
(p < 0.001) in IL-6 values between controls
(26.29 pg/ml ± 6.25) and diabetics
(194.77pg/ml ± 166.16).The mean waist
circumference (WC) for diabetics (100.75
cm ± 18.47) and controls (88.77 cm ±
13.36), and waist-hip-ratio for diabetics
(1.01 ± 0.14) and controls (0.88 ± 0.07),
showed significant differences (p value;
0.043 and 0.002 respectively). However,
there was no significant difference (p =
0.871) in mean BMI between diabetics
(26.99kg/m2 ± 5.34) and  controls
(27.29kg/m2 ± 5.61).
We did not find any significant
difference in the mean values for of the
other analytes measured in diabetics
versus controls. (P< 0.05).This was in
spite of the fact that values were higher
in diabetics than controls, except for
albumin and HDL-C. The small number
of subjects enrolled in the study may be
responsible for this.
Among diabetics and controls,
there was no sex impact on the mean
values of the analytes measured. (p<
0.05).
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Correlation  Analyses
Among subjects with diabetes
mellitus, we found significant corre-
lations between IL-6 and Tg (p<0.01, r =
0.007**), IL-6 and LDL-C (p<0.05, r =
0.028*), IL-6 and AST (p<0.05, r = 0.041*)
and IL-6 and ALT (p<0.01, r = 0.004**)
When we combined the groups
(patients and controls) there were more
significant correlation relationships; IL-
6 correlated with WHR (p<<0.01, r =
0.006**), Tg (p<0.01, r = 0.002**), AST
(p<0.01, r = 0.003**), ALT (p<0.01, r =
0.004**), FBS (p<0.01, r = 0.007**). There
was no significant correlation between
IL-6 and BMI (p<0.05, r = 0.441) and WC
(p<0.05, r = 0.325).
DISCUSSION
The significant age difference
between diabetics and controls in this
study is not surprising. This is because
diabetes mellitus is commonly a disease
of older hospital patients (mean age < 50
years) in Nigeria22–24 and other developing
countries.25 Since insulin resistance and
glucose intolerance are present for up to
a decade or more before the advent of
frank diabetes mellitus, it will be important
to commence, efforts aimed at preventing
or slowing diabetes in Nigerians, early.
This study did not find any
significance difference in BMI, SBP, DBP,
TC and Tg in the diabetics compared to
non-diabetic controls, a result similar to
what others have recorded. In a 2011
study in Iran, there was no significant
difference in mean values of variables
listed  above,  except  for  HDL-C  and
LDL-C.26
The waist circumference and waist
hip ratio, but not BMI, showed the impact
of difference in body size and shape
between diabetics and controls. This was
particularly demonstrated by WHR, thus
supporting the relevance of abdominal
Table 1:  Descriptive Characteristics of the General Population
Variables                                                                            Mean                                 SD ±
Age 51.83 13.28
Systolic blood pressure 124.88 15.39
Diastolic blood pressure 80.22 9.21
Body mass index (kg/m2) 27.09 5.36
Waist circumference (cm) 96.95 17.77
Waist hip ratio 0.97 0.13
Fasting plasma glucose(mmol/L) 6.72 2.70
ALT (mIU/L) 11.24 3.99
AST (mIU/L) 25.12 13.62
Total Protein (g/L) 73.08 11.59
Albumin (g/L) 48.42 6.71
Urea (mmol/L) 2.94 1.30
Creatinine (mol/L) 61.26 43.77
Triglyceride (mmol/L) 1.45 0.90
Total cholesterol (mmol/L) 3.70 0.90
HDL-C (mmol/L) 1.00 0.38
LDL-C (mmol/L) 2.05 1.02
IL-6 (pg/ml) 125.06 166.29
Table 3: Comparison of Means of Variables between Diabetics and Controls
Variables Diabetics ± SD Controls ± SD Significance
(N=28) (N=13) (2 –Tailed)
Age 56.61 ± 9.62 41.54 ± 14.55 0.000
Systolic blood pressure 125.71 ± 14.25 123.08 ± 18.09 0.616
Diastolic blood pressure 79.07 ± 8.70 82.69 ± 10.13 0.246
Body mass index (kg/m2) 26.99 ± 5.34 27.29 ± 5.61 0.871
Waist circumference (cm) 100.75 ± 18.47 88.77 ± 13.36 0.043
Waist hip ratio 1.01  0.14 0.88 ± 0.07 0.002
Fasting plasma glucose (mmol/L) 7.78 ± 2.62 4.43 ± 0.82 0.000
ALT (mIU/L) 11.43 ± 4.31 10.85 ± 3.34 0.669
AST (mIU/L) 27.43 ± 15.32 20.15 ± 7.15 0.113
Total Protein (g/L) 71.85 ± 10.14 75.74 ± 14.33 0.390
Albumin (g/L) 47.18 ± 6.60 51.09 ± 6.39 0.083
Urea (mmol/L) 3.17 ± 1.12 2.43 ± 1.53 0.086
Creatinine (µmol/L) 62.94 ± 50.94 58.02 ± 26.44 0.748
Triglyceride (mmol/L) 1.55 ± 0.98 1.24 ± 0.69 0.311
Total cholesterol (mmol/L) 3.86 ± 0.72 3.34 ± 1.15 0.087
HDL-C (mmol/L) 0.95 ± 0.40 1.11 ± 0.33 0.228
LDL-C (mmol/L) 2.21 ± 0.89 1.68 ± 1.21 0.120
IL-6 (pg/ml) 194.77 ± 166.16 26.29 ± 6.65. 0.001
Table 2: Sex  Distribution among the Study Populations
Gender Whole Study Population Diabetics Controls
(%)  (%) (%)
Males 15 (36.6) 10 (35.7)   5 (38.5)
Females 26 (63.4) 18 (64.3)   8 (61.5)
Total 41 (100) 28 (100) 13 (100)
Table 4: Correlations among the
Diabetic  Population
Variables Correlation
IL-6 vs Tg P = 0.007  (0.568)
IL-6 vs LDL-C P = 0.028 (–0.455)
IL-6 vs AST P = 0.041 (0.376)
IL-6 vs ALT P = 0.004 (0.514)
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adiposity in insulin resistance and
diabetes mellitus. Furthermore, central
adiposity-related indicators (WC, WHR
and WC/WHR) have been found to
correlate better, than those assessing
body mass indexes, with plasma
proinflammatory markers such as IL-6.27
In humans, IL-6 is secreted by both
adipose and non-adipose stroma cells,
with a significant portion secreted by
adipose tissue. This secretion is mainly
from white adipose tissues and visceral
adipocytes.28,29 The marked difference in
the levels of IL-6 in diabetics and controls
among our patients did not show any
correlation with indices of central
adiposity (WC and WHR). This lack of
correlation was also found some other
studies30,31 but not in all.32,33
Various studies have shown
increase in IL-6 levels in diabetic
subjects34–37 and this high cytokine level
is reported tobe contributory to the
development of complications in
diabetes.38–40   It has been reported that,
proinflammatory cytokines such as IL-6,
TNFa and CRP are elevated in patients
before they become overtly diabetic,41,42
thus adding to the importance of tracking
cytokines before and after development
of diabetes mellitus. Increased level of
IL-6 in these subjects could be related to
noted abdominal fat mass in relation to
controls as evident by their mean WC
and WHR. This has been found in other
works which reveals high levels of IL-6
with increasing abdominal adiposity.43–45
We are unable to categorically say
observed high IL-6 is due to central
adiposity due to the lack of correlation
between the two factors.
The elevated levels of IL-6 in insulin
resistant state could contribute to
progression from glucose intolerance to
frank diabetes by increasing expression
of suppressor of cytokine signalling 3
(SOCS-3), impaired phosphorylation of
IRS-1 and PkB/Akt46 and down regulation
of GLUT-4.47
One opinion is that high level of IL-
6 in subjects with abdominal obesity may
be responsible for observed increased
energy expenditure through induction of
lipolysis and elevated fatty acid
oxidation.48,49 Even for similar body fat, it
has been noted that subjects with higher
level of IL-6 shows higher omental
lipolysis, again supporting a key forthe
cytokine in adipocyte metabolism. 50 This
may account for the observed negative
correlation between IL-6 and abdominal
obesity, in one study.49,51 In the present
study, we did not find any significant
correlation between abdominal adiposity
(WC and WHR) and IL-6 among the
diabetic subjects, but in the controls. We
therefore thought that elevated IL-6 in
our patients maybe coming from a non-
natural adipose storage site.
This seeming discrepancy may be
affected by the multiple sources of IL-6
in the body. It is known that up to 25% of
systemic IL-6 comes from subcutaneous
adipose tissue, where it still can alter
glucose and lipid metabolism.52,53
Given the significant correlation
between IL-6 with AST and ALT we
suspect that elevated IL-6 in our patients
may have hepatic origin. It is known that
liver pathology such as non-alcoholic
liver disease (NALD) is a common finding
in DM patients, especially in the
presence of high level of  IL-6.54 An earlier
study showed a similar relationship
between IL-6 and hepatic transaminases
in insulin resistant patients. This study
noted that there was also increased
Caspase-generated cytokeratin-18 (CK-
18), a marker of hepatic cell apoptosis, in
patients with high IL-6 and elevated
transaminases. 55  The assault on the liver
by DM2 maybe worsened in the presence
of visceral adiposity as a result of
increased intra-abdominal adipocytes
lipolysis and resultant lipo-hepatic
toxicity.56
In spite of the non-significant
differences in means of lipid parameters
in diabetics versus controls, there was a
significant correlation between IL-6 and
Tg, and IL-6 and LDL-C. The suggestion
from this is that there is a possible
increase of IL-6 by abnormal lipid levels,
or the elevated IL-6 due to insulin
resistance and diabetes state affects the
levels of lipids. Apart from this study,
others have shown a correlation between
IL-6 and LDL-C40,55 It is possible that the
lack of significant difference between
subjects with diabetes mellitus and
controls, maybe linked to the lipid
lowering ability of IL-6.57 However, it
should be noted that high level of IL-6
has been related also to increased
amount of oxidised-LDL in diabetic
subjects.26
In the last couple of years, IL-6 has
been noted to also have anti-inflamma-
tory properties, aside the traditional
description as a pro-inflammatory
cytokine. This feature includes its ability
to decrease secretion of TNF-alpha, IFN-
gamma and increase levels of IL-1R-
antagonists and TNF receptor, in the
course of inflammation.58 The particularly
high levels of IL-6 warrants particular
mention, even among the controls albeit
hospital patients. However, reports
already noted that blacks have higher IL-
6  levels  than  whites,59,60  and  the  level
of this cytokine has been found to be
higher in low socio-economic status
individuals.61,62 The impact of low socio-
economic status might not be significant
here as almost 70% of the diabetic
population had a post-secondary
certificate (result not shown). Further-
more, the G/G IL-6 genotype variation
which is said to result in higher levels of
IL-6 production has been mainly
described in blacks.63
The high level of IL-6 found in
diabetes mellitus patients in Nigeria
appears to be more related to hepatic
disorders than observed higher measures
of central adiposity in them. While it
advisable to have measures to address
increased central adiposity in diabetic
patients in the region, we here suggest
further study of the state of the liver in
the patients. Such further studies may
reveal other issues that may be related to
the high level of IL-6 in Nigerian DM2
patients.
Shortcoming: The short coming we
notice in this work is the small number of
subjects enrolled in it.
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